On Thursday, 11 November 2021, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its nine-month interim report (Q3) 2021.
ALK will host a meeting for analysts and institutional investors that day at 1.30pm (CET) at which Management will review the financial results, the outlook and answer questions.
The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins.
Participants in the conference call are kindly requested to call in before 1.25pm (CET). Danish participants should call in on tel. +45 3544 5577 and international participants should call in on tel. +44 333 300 0804 or +1 631 913 1422. Please use the following participant pin code: 25705608#
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,500 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize…
Provides financial flexibility by reducing near-term debt maturities, deferring principal redemption payment, and reducing near-term…
Innovative Solutions Transform Treatment for Burn Victims, Chronic Wounds, and Scar ReductionCHICAGO, Dec. 31, 2024…
TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…
HOUSTON--(BUSINESS WIRE)--Hamershlag Private Capital Management Limited (HPCM), a leading health technology investment firm, has announced…
HOUSTON--(BUSINESS WIRE)--Hamershlag Private Capital Management Limited (HPCM), a leading health technology investment firm, has announced…